NCT07470840 2026-03-17
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
Clinical Trials
56 trialsNCT05616650 2026-03-13
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05361798 2026-03-12
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07451795 2026-03-05
SHARP
Fudan University
Phase 2 Recruiting
NCT07414992 2026-02-17
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Not yet recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT07393867 2026-02-06
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Not yet recruiting
NCT03902951 2026-02-05
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03796767 2026-01-28
SOAR
University of Utah
Phase 2 Active not recruiting
NCT06397703 2026-01-28
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NYU Langone Health
Phase 2 Recruiting
NCT03503344 2026-01-21
PILLAR
University of California, San Francisco
Phase 2 Completed
NCT05038332 2026-01-16
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT05053152 2026-01-14
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Recruiting
NCT05830058 2026-01-05
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT04974671 2025-12-04
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Yale University
Phase 2 Recruiting
NCT05893381 2025-12-03
LUST
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT03436654 2025-11-28
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03541850 2025-11-06
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02713269 2025-10-30
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03575611 2025-10-28
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05241340 2025-10-24
RAD-VACCINE
The Methodist Hospital Research Institute
Phase 2 Active not recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06927635 2025-09-05
SECURE
University Health Network, Toronto
Phase 2 Recruiting
NCT06255223 2025-09-03
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Jinling Hospital, China
Phase 2 Recruiting
NCT07152067 2025-09-03
TOPPGUN-RS
Centre Hospitalier Universitaire de Liege
Phase 2 Not yet recruiting
NCT04090710 2025-08-03
CYTOSHRINK
Ontario Clinical Oncology Group (OCOG)
Phase 2 Active not recruiting
NCT03298087 2025-08-01
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
VA Office of Research and Development
Phase 2 Completed
NCT04915508 2025-06-22
EXCALIBUR
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05915442 2025-05-20
SBRT-AMICO
Columbia University
Phase 2 Recruiting
NCT05496959 2025-05-13
LUNAR
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05169970 2025-05-08
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03361735 2025-05-02
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04262154 2025-04-27
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06201078 2025-03-13
PROSTARE
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting
NCT04580836 2024-10-26
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05655715 2024-10-16
CheckPRO
Herlev and Gentofte Hospital
Phase 2 Completed
NCT03795207 2024-08-02
POSTCARD
Institut Cancerologie de l'Ouest
Phase 2 Active not recruiting
NCT02978404 2024-06-28
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Completed
NCT06251492 2024-02-20
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
Fudan University
Phase 2 Unknown
NCT00003308 2023-06-22
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02680587 2022-11-29
ORIOLE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05212857 2022-03-16
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Fudan University
Phase 2 Unknown
NCT02599779 2021-09-01
OZM-065
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT01896271 2021-08-23
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT03065179 2021-03-30
RADVAX
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02019576 2021-03-23
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT03380806 2020-06-04
PBS
Juravinski Cancer Center
Phase 2 Unknown
NCT01439542 2018-08-09
FASTR
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Terminated